These findings, presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), confirm that the Deciparticle™technology represents a ...
News
- Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of ...
- bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American ... - Nasdaq
SAN ANTONIO, Texas--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive ...
- PreciseDxR Presents New Data for PreciseBreastR, an AI Digital Pathology Test to Predict ...
Three abstracts will be presented during the annual San Antonio Breast Cancer Symposium (SABCS) taking place December 9-12, 2025, in San Antonio, TX.
- Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio ...
... biotechnology company focused on the discovery and development of proprietary cancer. ... San Antonio Breast Cancer Symposium (SABCS), in San Antonio, ...
- Collaborative research program aims to revolutionize cancer treatment
The University of Texas at San Antonio (UT San Antonio) was recently awarded a $10 million program project grant from the National Cancer ...